News

#AAN2018 – Potential Huntington’s Treatment Halts Loss of Brain Volume, Improves Metabolism, Study Finds

Treatment with investigational medication VX15/2503 halts disease-related loss of brain volume and improves its metabolic activity in Huntington’s disease patients, according to a Phase 2 clinical study. The research, “Clinical Development of VX15/2503 Anti-Semaphorin 4D Antibody as a Potential Treatment for Huntington’s Disease,” was presented by Elizabeth Evans, PhD,…

#AAN2018 – IONIS-HTTRx Shows Promise in Phase 1/2 Trial to Treat Early-stage Huntington’s

The investigative therapy IONIS-HTTRx effectively reduced levels of the protein responsible for Huntington’s disease in early-stage patients, according to the findings of an ongoing Phase 1/2 clinical trial. The results also revealed that IONIS-HTTRx is generally safe and well-tolerated by patients, further demonstrating its potential as an alternative therapeutic option…